Skip to main content

Biogen Revenue from anti-CD20 therapeutic programs revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Revenue from anti-CD20 therapeutic programs revenue at Biogen came to $497.3M for the quarter to 30 Sep 2026, up 0.7% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$435.8MDec 2023$394.0MMar 2024$444.5MJun 2024$446.2MSep 2024$465.2MDec 2024$378.2MMar 2025$467.3MJun 2025$493.9MSep 2025$521.2MDec 2025$419.1MMar 2026$513.5MJun 2026$497.3MSep 2026
Biogen Revenue from anti-CD20 therapeutic programs revenue, every reported period
Period endingRevenue from anti-CD20 therapeutic programs revenueChange on a yearFiled
30 Sep 2026$497.3Mup 0.7%28 Oct 2026
30 Jun 2026$513.5Mup 9.9%29 Jul 2026
31 Mar 2026$419.1Mup 10.8%29 Apr 2026
31 Dec 2025$521.2Mup 12.0%6 Feb 2026
30 Sep 2025$493.9Mup 10.7%30 Oct 2025
30 Jun 2025$467.3Mup 5.1%31 Jul 2025
31 Mar 2025$378.2Mdown 4.0%1 May 2025
31 Dec 2024$465.2Mup 6.7%12 Feb 2025
30 Sep 2024$446.2Mup 6.0%30 Oct 2024
30 Jun 2024$444.5Mup 2.6%1 Aug 2024
31 Mar 2024$394.0Mdown 1.4%24 Apr 2024
31 Dec 2023$435.8Mdown 2.7%14 Feb 2024
30 Sep 2023$420.9Mup 1.0%8 Nov 2023
30 Jun 2023$433.4Mdown 0.7%25 Jul 2023
31 Mar 2023$399.5Munchanged25 Apr 2023
31 Dec 2022$447.9Mup 8.2%15 Feb 2023
30 Sep 2022$416.9Mup 0.4%25 Oct 2022
30 Jun 2022$436.3Mdown 0.8%20 Jul 2022
31 Mar 2022$399.4Mup 2.7%3 May 2022
31 Dec 2021$414.1Mdown 1.2%3 Feb 2022
30 Sep 2021$415.4Mdown 25.8%20 Oct 2021
30 Jun 2021$440.0Mdown 8.0%22 Jul 2021
31 Mar 2021$389.0Mdown 25.2%22 Apr 2021
31 Dec 2020$419.0Mdown 30.3%3 Feb 2021
30 Sep 2020$560.1Mdown 6.0%21 Oct 2020
30 Jun 2020$478.3Mdown 17.0%22 Jul 2020
31 Mar 2020$520.4Mup 0.6%23 Apr 2020
31 Dec 2019$600.8Mup 12.3%6 Feb 2020
30 Sep 2019$595.8Mup 16.4%22 Oct 2019
30 Jun 2019$576.4Mup 17.5%24 Jul 2019
31 Mar 2019$517.4Mup 16.7%24 Apr 2019
31 Dec 2018$534.9Mup 28.9%6 Feb 2019
30 Sep 2018$511.7Mup 25.9%23 Oct 2018
30 Jun 2018$490.4Mup 23.5%24 Jul 2018
31 Mar 2018$443.2Mup 30.1%24 Apr 2018
31 Dec 2017$415.0M—1 Feb 2018
30 Sep 2017$406.5M—24 Oct 2017
30 Jun 2017$397.1M—25 Jul 2017
31 Mar 2017$340.6M—25 Apr 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.